Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

Lancet

Volumn 352, Issue 9139, 1998, Pages 1491-1497

  Kappos, Ludwig ^a   Polman, Chris ^b   Pozzilli, Carlo ^b   Thompson, Alan ^b   Dahlke, Frank ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; STEROID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INJECTION PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; WHEELCHAIR;

EID: 0032494792     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10039-9     Document Type: Article

References (22)

1. 1 IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-61.
2. 2 Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
3. 3 Ebers GC, Oger J, Paty D. The multiple sclerosis PRISMS study: prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis (abstr). Ann Neurol 1997; 42: 986.
4. 4 Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 1998; 64: 444-50.
5. 5 Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 1983; 33: 1444-52.
6. 6 Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988; 38: 1793-98.
7. 7 Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259-74.
8. 8 Polman CH, Dahlke F, Thompson AJ, et al. Interferon beta-1b in secondary-progressive multiple sclerosis: outline of the clinical trial. Mult Scler 1995; 1: 51-54 (suppl).
9. 9 Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
10. 10 Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 48: 907-11.
11. 11 Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, Canadian Cooperative MS Study Group. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 40: 971-75.
12. 12 Lechner-Scott J, Huber S, Kappos L. Expanded disability status scale (EDSS) training for MS-multicenter-trials. J Neurol 1997; 244 (suppl 3): 25.
13. 13 Lleonart R, Näf D, Browning H, Weissmann C. A novel, quantitative bioassay for type I intereron using a recombinant indicator cell line. Biotechnology 1990; 8: 1263-67.
14. 14 Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-89.
15. 15 Petkau J. Statistical and design considerations for multiple sclerosis clinical trials. In: Goodkin DE, Rudick RA, eds. Advances in MS clinical trial design, treatment, and future perspectives. Heidelberg: Springer, 1996: 63-104
16. 16 Koch GG, Edwards S. Clinical effiacy trials with categorical data. In: Peace KE (ed). Biopharmaceutical statistics for drug development. New York: Marcel Dekker, 1988: 403-57.
17. 17 Petkau, J and White R. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis (abstr). Mult Scler 1997; 3: 402.
18. 18 Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987; 14: 255-61.
19. 19 Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-82.
20. 20 The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomised, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591-605.
21. 21 Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996; 46: 1613-19.
22. 22 Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-46.